Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878643 · ClinicalTrials.gov registry record · Early Phase 1
Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit
A Early Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 47
- Enrollment target
NCT01878643: Completed Early Phase 1 study, sponsored by Stony Brook University.
NCT01878643 is a Early Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 47 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01878643, a Early Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study was : * to determine the effect of inhaled antibiotics on airway bacteria in ventilated patients * to determine the effect of inhaled antibiotics on respiratory infection
Primary Outcome
Tracheal aspirates are taken at randomization. Randomization to drug is determined by the Gram stain(organisms are Gram-positive, Gram-negative or both). End of treatment culture, susceptibility and Gram stain of tracheal aspirate is taken after 14 days of treatment or at time of extubation, (which ever comes first). Eradication is defined as absence of growth in culture and absence of organisms on Gram stain.
Interventions
- DRUG Placebo
- DRUG vancomycin or gentamicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2001-12 |
| Est. Completion | 2002-12 |
| Phase | Early Phase 1 |
What the finished NCT01878643 record still lists
NCT01878643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01878643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01878643 about?
NCT01878643 is a clinical study titled "Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit". The purpose of this study was : * to determine the effect of inhaled antibiotics on airway bacteria in ventilated patients * to determine the effect of inhaled antibiotics on respiratory infection
What is the current status of trial NCT01878643?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 47 participants. The study started on 2001-12. Estimated completion is 2002-12.
What interventions are being tested in trial NCT01878643?
The interventions under investigation include: Placebo (DRUG), vancomycin or gentamicin (DRUG).
Who is sponsoring clinical trial NCT01878643?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01878643's enrollment target sits among peer trials
47 563rd of 2000 higher than 1,435 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia